Tear protein biomarkers of refractive surgery pain

屈光手术疼痛的泪液蛋白生物标志物

基本信息

批准号：
10786192
负责人：
SUE A AICHER
金额：
$ 88.37万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10786192
关键词：
Ablation Acute Pain Age Algorithms American Bathing Biological Biological Assay Biological Markers Biometry Categories Clinical Collection Consensus Cornea Corneal Injury Corneal pain Detection Development Diagnostic Disease Disease Progression Excision Eye Eye diseases Feeling suicidal Future Goals Hour In Situ Individual Knowledge Lasers Link Lipids Liquid substance Mass Spectrum Analysis Measures Mental Health Methods Morbidity - disease rate Nerve Nociception Non-Steroidal Anti-Inflammatory Agents Normal Range Numeric Rating Scale Operative Surgical Procedures Ophthalmologic Surgical Procedures Opioid Oral Outcome Pain Pain Measurement Pain management Participant Patients Persistent pain Phase Photorefractive Keratectomy Population Postoperative Pain Probability Procedures Prognostic Marker Protein Analysis Proteins Proteomics Quality of life Refractive Errors Reporting Reproducibility Risk Sampling Sensory Nerve Endings Smoking Status Source Suicide Surface Therapeutic Treatment Efficacy United States Validation Variant Vision Visit Vulnerable Populations Water Work analytical method antinociception biomarker signature biomarker validation combat corneal ablation corneal epithelium diagnostic biomarker experience eye dryness improved keratomileusis ocular pain pain reduction pain score patient population patient screening patient stratification predictive marker prognostic prognostication protein biomarkers recruit resilience response sex surgical pain tear proteins

项目摘要

PROJECT SUMMARY Photorefractive keratectomy (PRK) and laser-assisted in situ keratomileusis (LASIK) are surgical procedures used to correct refractive errors, with approximately 600,000 surgeries performed in the United States each year. A proportion (10 - 20%) of individuals develop persistent ocular pain after refractive surgery, which is a source of tremendous morbidity, limiting the ability to work, impacting mental health, and leading to suicidal ideation in severe cases. We hypothesize that proteins in the tear fluid modulate corneal nerve function, increasing the risk of and contributing to persistent pain after refractive surgery. As such, our studies will use proteomic analysis of tear fluid after surgery to identify diagnostic biomarkers for persistent ocular pain. We will also examine tear proteins prior to surgery in an effort to identify prognostic biomarkers that predict which individuals are likely to develop persistent pain after surgery. R33 Phase studies will use an alternative proteomics platform for analytical validation, and an additional new patient population for clinical validation. This knowledge can lead to better preventative and therapeutic algorithms to combat this debilitating condition and thus improve quality of life and decrease patient suffering.

项目概要屈光性角膜切削术（PRK）和激光辅助原位角膜磨镶术（LASIK）用于矫正屈光不正的外科手术，约有 600,000 例手术每年都在美国演出。一部分 (10 - 20%) 的个体发展为屈光手术后持续的眼部疼痛，这是巨大发病率的根源，限制工作能力，影响心理健康，严重时会导致自杀意念案例。我们假设泪液中的蛋白质调节角膜神经功能，增加屈光手术后持续疼痛的风险并导致持续性疼痛。因此，我们的研究将利用手术后泪液的蛋白质组学分析来识别诊断生物标志物持续性眼部疼痛。我们还将在手术前检查泪液蛋白，以确定预后生物标志物可预测哪些个体在术后可能会出现持续性疼痛外科手术。 R33 阶段研究将使用替代蛋白质组学平台进行分析验证，以及用于临床验证的额外新患者群体。这些知识可以导致更好的预防和治疗算法来对抗这种令人衰弱的状况，从而提高生活质量并减少患者痛苦。